Quarterly Activities/Appendix 4C Cash Flow Report

Key points

• Atomo secures $440k order for HIV Self-Tests in Australia
• Executes $2.44M grant for active syphilis test development
• Revenue of $1.2m in Q2 FY25, bringing H1 revenue to ~$2.1m

Full summary

Atomo Diagnostics Limited (ASX: AT1) has released its Appendix 4C and quarterly activity report for the three months ended 31 December 2024 (Q2 FY25). Key highlights include:- Atomo secures an order worth $440k for supply of HIV Self-Tests in Australia, with the first batch delivered in December. This represents further evidence of increasing adoption of self-testing in public health procurement policy.- Atomo executes a $2.44 million Cooperative Research Centres Projects (CRC-P) grant with the Commonwealth Government to complete the development of a novel rapid test for syphilis being developed on the Pascal cassette.- Revenue of $1.2m (unaudited) in Q2 FY25, bringing total H1 revenue (unaudited) to ~$2.1m. Cash receipts from customers during the quarter were $1.7m, with a further $753k received from Government R&D rebate and $485k for the CRC-P active syphilis grant.- Atomo continues to work on adapting its capabilities and IP to address new markets, including the development of the Florey clip-in blood test device and a standalone blood transfer device.- Key priorities for 2025 include growing HIV sales channels, progressing the Pascal syphilis program, and expanding OEM sales channels.

Guidance

Atomo reported unaudited revenue of $1.2m in Q2 FY25, bringing total H1 FY25 revenue to ~$2.1m.

Outlook

Atomo is focused on growing its HIV sales channels, progressing the Pascal syphilis program, and expanding OEM sales channels in 2025.